Screener
BioCryst Pharmaceuticals BCRX Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income (loss) from operations | 98,465 | 29,786 | (603,133) | 51,013 |
| Other income (expense): | ||||
| Interest income | 2,434 | 2,516 | 4,690 | 5,540 |
| Interest expense | (21,712) | (21,582) | (41,491) | (45,076) |
| Foreign currency gains (losses), net | 27 | (63) | (198) | (62) |
| Loss on extinguishment of debt | — | (4,171) | — | (4,171) |
| Other income (expense), net | 260 | — | (1,202) | — |
| Total other expense, net | (18,991) | (23,300) | (38,201) | (43,769) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's interest expense?
- BioCryst Pharmaceuticals (BCRX) reported interest expense of $21.71M in Q2 2026.
- How has BioCryst Pharmaceuticals's interest expense changed year-over-year?
- BioCryst Pharmaceuticals's interest expense increased by 0.6% year-over-year, from $21.58M to $21.71M.
- What is the long-term trend for BioCryst Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's interest expense has grown at a 7.4% compound annual growth rate (CAGR), from $59.29M to $78.87M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about BioCryst Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude